<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations of polycystic ovary syndrome in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations of polycystic ovary syndrome in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations of polycystic ovary syndrome in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David A Ehrmann, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Snyder, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William F Crowley, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Martin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 07, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The polycystic ovary syndrome (PCOS) is an important cause of both menstrual irregularity and androgen excess in women. When fully expressed, the manifestations include irregular menstrual cycles, hirsutism, acne, and, frequently, obesity. The clinical manifestations of PCOS will be reviewed here. The epidemiology and pathogenesis of, diagnostic criteria for, and treatment of PCOS are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         PCOS is one of the most common endocrinopathies in women of reproductive age, affecting between 6.5 and 10 percent of women overall [
         <a href="#rid1">
          1,2
         </a>
         ]. In a meta-analysis of 55 population-based studies from Europe, Australia, Asia, and the United States, the rates of hirsutism, hyperandrogenemia, polycystic ovaries, and oligo-ovulation were 13, 11, 28, and 15 percent, respectively [
         <a href="#rid3">
          3
         </a>
         ]. The epidemiology of PCOS is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p>
         It is important to appreciate that PCOS is a syndrome, reflecting multiple potential etiologies and variable clinical presentations. Its key features are oligo- or anovulation and hyperandrogenism. Other features are polycystic ovaries on pelvic ultrasonography, infertility due to oligo-ovulation, obesity, and insulin resistance.
        </p>
        <p class="headingAnchor" id="H552091663">
         <span class="h1">
          REPRODUCTIVE ABNORMALITIES
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Menstrual dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         The menstrual dysfunction in PCOS is characterized by oligo- or amenorrhea, caused by infrequent or absent ovulation. The menstrual disturbances classically have a peripubertal onset. Affected women may have a normal or slightly delayed menarche followed by irregular cycles. Other women may apparently have regular cycles at first and subsequently develop menstrual irregularity in association with weight gain. Although the mechanism is not fully elucidated, many obese women with PCOS resume more regular menstrual cycles with even modest weight loss. (See
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Weight reduction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H261220481">
         <span class="h3">
          Gonadotropin dynamics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many, but not all, women with PCOS have abnormal gonadotropin secretory dynamics. Most commonly, there is an increase in mean luteinizing hormone (LH) levels  (
         <a class="graphic graphic_figure graphicRef52544" href="/z/d/graphic/52544.html" rel="external">
          figure 1
         </a>
         ) and in LH pulse frequency and amplitude when blood is sampled frequently (a minimum of every 10 minutes throughout the day) [
         <a href="#rid4">
          4,5
         </a>
         ]. The likelihood of finding an elevation in serum LH depends upon the timing of the sample relative to the last menstrual period, the ovarian activity, the use of oral contraceptive (OC) pills, body mass index (BMI), and the frequency of LH sampling [
         <a href="#rid5">
          5
         </a>
         ]. Thus, the absence of an elevated serum LH level does not exclude the diagnosis of PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         The serum concentration of follicle-stimulating hormone (FSH) may be normal or low in PCOS, leading to an elevated LH/FSH ratio compared with normally cycling, early follicular phase, young control women. However, neither an elevated serum LH concentration nor an increased LH/FSH ratio is part of the diagnostic criteria for PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p>
         It has been proposed that in utero exposure to androgens may program the female fetus to develop LH excess, ovarian and adrenal hyperandrogenism, amenorrhea, and insulin resistance at puberty [
         <a href="#rid6">
          6-8
         </a>
         ].
        </p>
        <p>
         Genetic analyses suggest that women with PCOS have an increased prevalence of allelic differences in FSH beta chain gene that are associated with increased LH concentration [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults", section on 'Genetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Endometrial cancer risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         In PCOS, chronic stimulation of the endometrium by estrogen in the presence of chronically low progesterone levels associated with anovulation may result in an excess risk of endometrial hyperplasia and endometrial carcinoma. A national cohort study that included over 12,000 women with PCOS (with no information on treatment history) reported an increased risk of endometrial cancer [
         <a href="#rid10">
          10
         </a>
         ]. However, the excess absolute risk was very small (1.3 per 10,000 women per year [for women under age 50 years]). A meta-analysis of five studies including 138 women with PCOS and 5593 controls without PCOS reported an excess risk of endometrial cancer among women with PCOS (odds ratio [OR] 2.79, 95% CI 1.31-5.95) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The reduction in ovulatory events in PCOS leads to deficient progesterone secretion and chronic exposure to estrogen. Thus, women with PCOS may have constant mitogenic stimulation of the endometrium (chronic estrogen stimulation, no progesterone for differentiation), leading to intermittent breakthrough bleeding and abnormal uterine bleeding (frequent or unusually heavy menstrual bleeding typically associated with anovulation).
        </p>
        <p>
         Women with PCOS have other risk factors for endometrial cancer, including chronic hyperinsulinemia, increased serum insulin-like growth factor-1 (IGF-1) concentrations, hyperandrogenemia, and obesity [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Although there is no consensus on monitoring for endometrial hyperplasia in these patients, one study suggested that in oligo-ovulatory women with PCOS, an endometrial thickness &lt;7 mm on transvaginal ultrasound was not associated with histologic evidence of endometrial hyperplasia [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H552092007">
         <span class="h2">
          Ovarian abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         The key ovarian findings in PCOS include multiple, small, preantral and antral follicles in a peripheral location, with an increased volume of stroma. Histologically, there is a thickened and sclerotic cortex of the ovary, giving the appearance of a smooth white capsule on gross examination [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H552092013">
         <span class="h3">
          Ultrasound appearance
         </span>
         <span class="headingEndMark">
          —
         </span>
         With new high-frequency transvaginal ultrasonography, the histologic findings can be corroborated noninvasively. A modified set of diagnostic criteria for PCOS (the Rotterdam criteria) has been published and is described in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Transvaginal ultrasound'
         </a>
         .)
        </p>
        <p>
         The Rotterdam ultrasound criteria include the presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter and/or increased ovarian volume (&gt;10 mL; calculated using the formula 0.5 x length x width x thickness). Ovarian volume and follicle number decrease with age in women with or without PCOS. Age-based criteria to define polycystic ovaries have therefore been proposed in women over age 40 years. The International PCOS Network has proposed revised criteria because of improvements in the resolution of pelvic ultrasound [
         <a href="#rid15">
          15
         </a>
         ]. They suggest a threshold for diagnosing a polycystic/multifollicular ovary be increased to ≥20 follicles per ovary. The group also confirmed that an ovarian volume &gt;10 mL was consistent with PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Transvaginal ultrasound'
         </a>
         .)
        </p>
        <p>
         Using the original ultrasound criteria in combination with an ovarian volume greater than 10 mL (from revised criteria), nearly all women with irregular menses and hyperandrogenism have polycystic ovaries on ultrasound [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         As a sole finding, sonographically detected polycystic ovaries are not sufficient to make the diagnosis of PCOS, although they may represent a mild form of ovarian hyperandrogenism and insulin resistance. This was illustrated in a study of 68 nonhirsute women with normal menstrual cycles, 39 of whom had polycystic morphology on ultrasound [
         <a href="#rid17">
          17
         </a>
         ]. Serum total and free testosterone and dehydroepiandrosterone sulfate (DHEAS) were higher in the early follicular phase in women with polycystic morphology compared with those with normal ovarian morphology. In addition, both fasting insulin and insulin resistance calculated from a homeostasis model assessment of insulin resistance (HOMA-IR or HOMA model: fasting glucose x fasting insulin) were higher in the women with polycystic morphology.
        </p>
        <p>
         In a follow-up report from the same investigators, women with regular menstrual cycles and polycystic ovaries on ultrasound were not at increased risk for subsequent development of PCOS [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H552092036">
         <span class="h3">
          Follicular development
         </span>
         <span class="headingEndMark">
          —
         </span>
         Follicular development and function are abnormal in PCOS ovaries, including abnormal patterns of follicular fluid hormone production (low follicular fluid estradiol concentrations and high levels of follicular fluid androgens) [
         <a href="#rid19">
          19
         </a>
         ]. There are also abnormalities in the dynamics of follicular development. Growth of later (antral) stages of follicles tends to be arrested at 5 to 8 mm in diameter, much smaller than a mature follicle destined to ovulate.
        </p>
        <p>
         Although there is evidence for an abnormal ovarian endocrine environment, it is also possible that there is an intrinsic defect in ovarian folliculogenesis. As an example, in a histologic study of ovarian cortical biopsies in women with polycystic ovaries (either anovulatory or ovulatory) and normal controls, the density of small preantral follicles was sixfold greater in anovulatory women with polycystic ovaries compared with normals [
         <a href="#rid20">
          20
         </a>
         ]. Within the preantral follicular pool, the percentage of early growing (primary) follicles was significantly greater, the percentage of primordial (resting) follicles significantly lower, and there was a trend towards a greater percentage of atretic follicles in the anovulatory polycystic ovary patients compared with controls. These findings suggest that, although there might be a greater initial pool of follicles in women with PCOS, a higher percentage get recruited and then become atretic.
        </p>
        <p class="headingAnchor" id="H1560667514">
         <span class="h3">
          Serum AMH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum anti-müllerian hormone (AMH) is expressed by small (&lt;8 mm) preantral and early antral follicles; serum concentrations reflect the size of the primordial follicle pool. In adult women, AMH levels gradually decline with age (as the primordial follicle pool decreases) and become undetectable at menopause [
         <a href="#rid21">
          21
         </a>
         ]. In women with PCOS, mean AMH concentrations are high but overlap with those of age-matched women without PCOS [
         <a href="#rid22">
          22
         </a>
         ]. In a meta-analysis of 10 observational studies of women with PCOS, a serum AMH concentration &gt;4.7 ng/mL had a specificity and sensitivity for diagnosing PCOS of 79 and 83 percent, respectively [
         <a href="#rid23">
          23
         </a>
         ]. In one study, serum concentrations of AMH were two- to threefold higher in women with PCOS compared with normal ovulatory women [
         <a href="#rid24">
          24
         </a>
         ]. In addition, the number of small antral follicles detected on transvaginal imaging appears to be correlated with serum AMH concentrations [
         <a href="#rid25">
          25
         </a>
         ]. However, an elevated AMH is not currently considered to be a criterion for the diagnosis of PCOS, and available AMH assays are not yet well standardized [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H552091708">
         <span class="h2">
          Anovulatory infertility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with PCOS have infrequent ovulation and, therefore, often take longer to conceive. Many, if not most, women who have PCOS and oligo-ovulation and desire fertility eventually undergo ovulation induction therapies. Women who have PCOS may have other reasons for infertility as well since they have, in comparison with women with hypothalamic amenorrhea, a reduced rate of conception relative to the rate of ovulation after therapy with
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate. Infertility was included in the original description of PCOS [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7400.html" rel="external">
          "Ovulation induction with clomiphene citrate"
         </a>
         .)
        </p>
        <p>
         Many studies have also described an increased rate of early pregnancy loss in PCOS, the mechanism of which is poorly understood [
         <a href="#rid28">
          28
         </a>
         ], but may be related to obesity. (See
         <a class="medical medical_review" href="/z/d/html/5437.html" rel="external">
          "Recurrent pregnancy loss: Definition and etiology", section on 'Polycystic ovary syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H552092336">
         <span class="h2">
          Pregnancy complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of pregnancy complications is increased in women with PCOS. The spontaneous abortion rate in women with PCOS is 20 to 40 percent higher than the baseline in the general obstetric population [
         <a href="#rid29">
          29
         </a>
         ]. In addition, women with PCOS show higher risk of gestational complications, such as miscarriage, gestational diabetes mellitus (GDM), hypertension, and preeclampsia. These problems expose them to a higher risk of premature delivery and caesarean section [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         In a meta-analysis of 27 studies involving 4982 women with PCOS, the ORs of developing GDM, pregnancy-induced hypertension, preeclampsia, and preterm birth were 3.4, 3.4, 2.2, and 1.9, respectively, when compared with the general obstetric population [
         <a href="#rid31">
          31
         </a>
         ]. In addition, their babies had a higher risk of admission to the neonatal intensive care unit (NICU; OR 2.3). Obesity, in the absence of PCOS, is also a risk factor for these complications. The risk of GDM is increased in women with PCOS independent of BMI [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/433.html" rel="external">
          "Obesity in pregnancy: Complications and maternal management", section on 'Antepartum'
         </a>
         .)
        </p>
        <p>
         A prospective study of 150 pregnant women with PCOS suggests that the low-grade, chronic inflammation commonly seen in these patients, as evidenced by high serum concentrations of C-reactive protein (CRP), worsens during pregnancy and may be associated with excess risk of adverse pregnancy outcomes [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          HYPERANDROGENISM
         </span>
        </p>
        <p class="headingAnchor" id="H261220702">
         <span class="h2">
          Clinical
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperandrogenism is the second defining characteristic of PCOS. This is manifested clinically by hirsutism, acne, and female pattern hair loss. Women with PCOS do not develop virilization (deepening of the voice or clitoromegaly). If virilization occurs, other causes of hyperandrogenism should be investigated, including ovarian hyperthecosis or an androgen-secreting neoplasm of the ovary or adrenal gland. (See
         <a class="medical medical_review" href="/z/d/html/7397.html" rel="external">
          "Ovarian hyperthecosis"
         </a>
         .)
        </p>
        <p>
         Hirsutism is defined as excess terminal (thick, pigmented) body hair in a male distribution and is commonly noted on the upper lip, chin, around the nipples (periareolar), and along the linea alba of the lower abdomen  (
         <a class="graphic graphic_picture graphicRef73544" href="/z/d/graphic/73544.html" rel="external">
          picture 1
         </a>
         ). The approach to evaluation and management of hirsutism is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">
          "Evaluation of premenopausal women with hirsutism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">
          "Management of hirsutism in premenopausal women"
         </a>
         .)
        </p>
        <p>
         Adolescent hyperandrogenemia may be a harbinger of adult PCOS, and clinical manifestations of PCOS often have a peripubertal onset. Two studies of peripubertal girls suggest that obesity contributes to the hyperandrogenemia, as increasing body mass index (BMI) was associated with increases in serum total testosterone, free testosterone, and dehydroepiandrosterone sulfate (DHEAS) concentrations [
         <a href="#rid33">
          33,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5852.html" rel="external">
          "Definition, clinical features, and differential diagnosis of polycystic ovary syndrome in adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H261220709">
         <span class="h2">
          Biochemical
         </span>
         <span class="headingEndMark">
          —
         </span>
         Depending upon the androgen measured and the technique employed, between 50 and 90 percent of PCOS women have elevated serum androgen levels  (
         <a class="graphic graphic_figure graphicRef72842" href="/z/d/graphic/72842.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid35">
          35
         </a>
         ]. In women who present with hyperandrogenic symptoms, we measure serum total testosterone concentrations because it provides the best overall estimate of androgen production in hirsute women [
         <a href="#rid36">
          36
         </a>
         ]. Although serum free testosterone may be the more sensitive test for the presence of hyperandrogenic disorders [
         <a href="#rid37">
          37
         </a>
         ], currently available direct assays are inaccurate. If free testosterone is ordered, the method should be equilibrium dialysis. (See
         <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">
          "Evaluation of premenopausal women with hirsutism", section on 'Biochemical testing'
         </a>
         .)
        </p>
        <p>
         In one report of 1000 consecutive women with androgen excess, most of whom had PCOS, 78 percent had high serum androgens [
         <a href="#rid38">
          38
         </a>
         ]. Total testosterone, free testosterone, and DHEAS concentrations were elevated in 38, 55.5, and 40 percent, respectively. Among women with PCOS, DHEAS is increased in approximately 16 percent of women who have normal total and free testosterone levels. A mildly elevated level in the setting of normal free testosterone is unlikely to affect management. (See
         <a class="medical medical_review" href="/z/d/html/7442.html" rel="external">
          "Steroid hormone metabolism in polycystic ovary syndrome"
         </a>
         .)
        </p>
        <p>
         Serum androstenedione is sometimes elevated in women with PCOS. However, its role in the evaluation of PCOS and/or hirsutism is unclear [
         <a href="#rid39">
          39
         </a>
         ]. Its measurement may be important for documenting hyperandrogenism in some populations with PCOS, including Icelandic women. (See
         <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">
          "Evaluation of premenopausal women with hirsutism", section on 'Hirsutism with oligomenorrhea/amenorrhea'
         </a>
         .)
        </p>
        <p>
         Some hyperandrogenic women have mildly elevated serum prolactin levels, but the etiology and clinical significance is uncertain [
         <a href="#rid40">
          40
         </a>
         ]. Levels of prolactin in excess of 40 mg/dL should prompt evaluation for other causes. (See
         <a class="medical medical_review" href="/z/d/html/6638.html" rel="external">
          "Clinical manifestations and evaluation of hyperprolactinemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          METABOLIC ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Obesity and insulin resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a controlled, systematic study has not been performed to determine the exact prevalence, most investigators find that at least one-half of women with PCOS are obese. Most women with PCOS are also hyperinsulinemic and insulin resistant, independent of obesity, compared with normal women [
         <a href="#rid41">
          41,42
         </a>
         ]. In addition, the prevalence of the metabolic syndrome in women with PCOS appears to be increased. (See
         <a class="local">
          'Metabolic syndrome'
         </a>
         below.)
        </p>
        <p>
         Hyperandrogenemia has a minor effect upon the insulin resistance of PCOS; however, hyperinsulinemia contributes to the hyperandrogenism both directly (through stimulation of androgen biosynthesis in the ovarian theca cell) and indirectly through its suppressive effects on sex hormone-binding globulin (SHBG) production by the liver. (See
         <a class="medical medical_review" href="/z/d/html/7442.html" rel="external">
          "Steroid hormone metabolism in polycystic ovary syndrome"
         </a>
         .)
        </p>
        <p>
         We currently do not recommend routine assessment of insulin resistance in a clinical setting, since it is not possible to determine the extent to which PCOS contributes to insulin resistance, independent of body weight and adiposity. In addition, the magnitude of insulin resistance does not appear to predict the clinical response to insulin-lowering therapies. This issue is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H261221120">
         <span class="h3">
          Nonalcoholic fatty liver disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), may be increased in women with PCOS [
         <a href="#rid43">
          43-45
         </a>
         ]. In one study, 21 of 70 women (30 percent) with PCOS had elevated serum alanine aminotransferase (ALT) concentrations [
         <a href="#rid43">
          43
         </a>
         ]. In contrast, in a population-based study of over 18,000 adults, an abnormal ALT was seen in only 2 percent of all women, 5 percent of women with type 2 diabetes, and 7 percent of obese women [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3625.html" rel="external">
          "Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H261220926">
         <span class="h3">
          Metabolic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the most recent National Health and Nutrition Examination Survey (NHANES) report (1999 to 2000), the prevalence of the metabolic syndrome (as defined by the National Cholesterol Education Program/Adult Treatment Panel [ATP] III criteria) in normal women ages 20 to 39 years was approximately 18 to 19 percent [
         <a href="#rid47">
          47
         </a>
         ]. Using the same diagnostic criteria, the prevalence appears to be much higher in women with PCOS, as illustrated by the following findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one retrospective study, 43 percent of PCOS patients had the metabolic syndrome, roughly twofold higher than that of age-matched women in the general population, as reported by the NHANES III [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a second study, the prevalence of metabolic syndrome in women with PCOS was approximately 47 percent, compared with 4 percent in age-matched (but not weight-matched) controls with regular menses and no hirsutism [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the third study, a secondary analysis of 394 women with PCOS participating in a randomized trial (thiazolidinedione versus placebo), the metabolic syndrome was common (33.4 percent of subjects), particularly in those with the highest insulin levels and body mass index (BMI) [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Recommendations for metabolic evaluation of women with PCOS are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          IGT/type 2 diabetes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The risk of type 2 diabetes is increased in PCOS, particularly in women with a first-degree relative with type 2 diabetes [
         <a href="#rid30">
          30,51-55
         </a>
         ]. As an example, in a study of 122 obese women with PCOS, 45 percent had either impaired glucose tolerance (IGT; 35 percent) or type 2 diabetes mellitus (10 percent) by age 40 years [
         <a href="#rid51">
          51
         </a>
         ]. The women with diabetes had a 2.6-fold higher prevalence of first-degree relatives with type 2 diabetes. In a subset of 25 women who underwent repeat oral glucose tolerance testing (OGTT) after a mean of 34 months, 40 percent had a deterioration in glucose tolerance.
        </p>
        <p>
         In a second study of 71 women with PCOS, the annual conversion rate from normal glucose tolerance to IGT was 17 percent [
         <a href="#rid56">
          56
         </a>
         ]. A retrospective study showed that prevalence of type 2 diabetes mellitus was 15 percent in PCOS patients and 2 percent in controls. It has also been suggested that up to 20 percent of PCOS patients have IGT or type 2 diabetes in the third decade [
         <a href="#rid3">
          3,57
         </a>
         ].
        </p>
        <p>
         Women with PCOS and a family history of type 2 diabetes may have an impairment in insulin secretion as well as insulin resistance [
         <a href="#rid52">
          52,58
         </a>
         ]. In a study of 33 women with PCOS and 48 of their first-degree relatives who underwent a frequently sampled intravenous glucose tolerance test, there was a significant familial (sibling) correlation for the acute insulin response to intravenous glucose [
         <a href="#rid53">
          53
         </a>
         ]. This suggests that there is a heritable component to beta cell dysfunction in families of women with PCOS. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults", section on 'Insulin secretion and action'
         </a>
         .)
        </p>
        <p>
         The frequency of diagnosis of type 2 diabetes may vary with the screening test used. This was illustrated in a report of 254 women with PCOS who underwent both a fasting blood glucose and a 75 g OGTT [
         <a href="#rid59">
          59
         </a>
         ]. The American Diabetes Association (ADA) criteria (based on fasting glucose) underestimated the prevalence of diabetes when compared with the World Health Organization (WHO) criteria (based on OGTT; 3.2 and 7.5 percent, respectively). Similar findings have been described in adults [
         <a href="#rid60">
          60
         </a>
         ] and in adolescents [
         <a href="#rid61">
          61
         </a>
         ] with PCOS, where two-hour post-OGTT blood glucose levels were abnormal in a greater percentage of subjects than were fasting glucose levels. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'
         </a>
         .)
        </p>
        <p>
         The often familial nature of PCOS has led to examination for possible molecular linkages of this disorder to type 2 diabetes. As an example, a unique defect in serine phosphorylation of the insulin receptor that results in decreased activation of the receptor has been identified in approximately 50 percent of women with PCOS [
         <a href="#rid62">
          62
         </a>
         ]. Why this occurs is not clear, but serine phosphorylation of
         <em>
          CYP17
         </em>
         may also be part of the mechanism of increased adrenal androgen synthesis [
         <a href="#rid63">
          63
         </a>
         ]. In addition, familial PCOS has been linked to an insulin regulatory locus on chromosome 11 [
         <a href="#rid64">
          64
         </a>
         ]. Whether this represents a common genetic defect in PCOS and diabetes or whether it reflects cosegregation of diabetes with PCOS in the tested families remains to be elucidated.
        </p>
        <p>
         The evaluation of women with PCOS for glucose intolerance, including guidelines from a number of professional organizations, is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'
         </a>
         .)
        </p>
        <p>
         The genetics of PCOS is also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults", section on 'Genetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H342301178">
         <span class="h2">
          Sleep apnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep apnea is common in women with PCOS [
         <a href="#rid65">
          65
         </a>
         ]; women with PCOS should be questioned about signs and symptoms of sleep apnea and excessive daytime sleepiness.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 53 women with PCOS compared with 452 premenopausal controls, obstructive sleep apnea (OSA) and excessive daytime sleepiness (diagnosed by an overnight sleep study or written questionnaire, respectively) were significantly more common in the PCOS group (odds ratio [OR] 30.6 and 9.0, respectively) [
         <a href="#rid66">
          66
         </a>
         ]. The differences remained significant, even when controlled for BMI. The strongest predictors for sleep apnea were fasting plasma insulin concentrations and glucose-to-insulin ratios. Similar results were seen in a second study [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In women with PCOS, glucose tolerance appears to be directly related to the severity of the sleep-disordered breathing [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         OSA appears to be an important determinant of insulin resistance, glucose intolerance, and type 2 diabetes in PCOS. This was illustrated in a prospective study of 52 women with PCOS and 21 women without PCOS (of similar age and BMI) who underwent an overnight polysomnogram and a 75 g OGTT [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Dyslipidemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most studies of women with PCOS have demonstrated low high-density lipoprotein (HDL) cholesterol and high triglyceride concentrations, consistent with their insulin resistance [
         <a href="#rid70">
          70
         </a>
         ], as well as an increase in low-density lipoprotein (LDL) cholesterol [
         <a href="#rid55">
          55,71-73
         </a>
         ]. The approach to metabolic screening of women with PCOS is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'
         </a>
         .)
        </p>
        <p>
         In one review of 195 obese and nonobese women with PCOS and 65 weight-matched controls, serum LDL cholesterol was increased in both the obese and nonobese PCOS groups when compared with controls (mean differences of 16 and 32 mg/dL [0.41 and 0.82 mmol/L], respectively) [
         <a href="#rid72">
          72
         </a>
         ]. In addition, HDL cholesterol was modestly but significantly elevated (6 mg/dL [0.16 mmol/L]) in the obese women with PCOS, which may provide some degree of protection against cardiovascular disease. Although serum triglyceride concentrations appeared higher in the PCOS patients, it was not a statistically significant difference.
        </p>
        <p>
         In a second study of 398 women with PCOS, the prevalence of abnormal lipid parameters was quite high [
         <a href="#rid74">
          74
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total cholesterol ≥200 mg/dL (5.27 mmol/L): 35 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LDL ≥130 mg/dL (3.36 mmol/L): 31 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HDL &lt;35 mg/dL (0.90 mmol/L): 15 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triglycerides &gt;200 mg/dL (2.26 mmol/L): 16 percent
        </p>
        <p>
        </p>
        <p>
         Women with PCOS are also more likely to have an increase in small, dense LDL particles when compared with women of similar BMI and insulin resistance without PCOS [
         <a href="#rid75">
          75,76
         </a>
         ]. Small, dense LDL is strongly associated with an increased risk of coronary heart disease (CHD).
        </p>
        <p class="headingAnchor" id="H261221887">
         <span class="h1">
          CORONARY HEART DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         There have been concerns that women with PCOS are at increased risk for coronary heart disease (CHD) and other cardiovascular events, but these risks are not well established [
         <a href="#rid77">
          77
         </a>
         ]. Nevertheless, we recommend that all cardiovascular risk factors be considered for evaluation and treatment. The presence of obesity, insulin resistance, impaired glucose tolerance (IGT) or type 2 diabetes, and dyslipidemia may predispose women with PCOS to CHD [
         <a href="#rid55">
          55
         </a>
         ]. The following observations illustrate the range of findings that have been described.
        </p>
        <p class="headingAnchor" id="H360467539">
         <span class="h2">
          Observational data
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on long-term CHD morbidity and mortality in women with PCOS are inconclusive.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one 30-year follow-up study of women who had previously undergone wedge resection surgery (presumably for PCOS) [
         <a href="#rid78">
          78,79
         </a>
         ], no increased mortality from cardiovascular disease was observed, in spite of an increased prevalence of cardiovascular risk factors, including diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, in the Nurses' Health Study, a history of menstrual cycle irregularity was associated with an increased risk of nonfatal and fatal CHD (relative risk [RR] 1.25 and 1.67, respectively) [
         <a href="#rid80">
          80
         </a>
         ]. This might be explained by a high rate of PCOS with its associated metabolic disturbances in these women, although no clinical or biochemical androgen data were available for confirmation of the PCOS diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A similar increase in CHD mortality was noted in a second prospective cohort study [
         <a href="#rid81">
          81
         </a>
         ]. However, the magnitude of the effect was attenuated after adjusting for body mass index (BMI). In addition, a subgroup analysis from the Women's Ischemia Syndrome Evaluation (WISE) reported that among postmenopausal women with possible ischemia, features of PCOS (history of irregular menses and current hyperandrogenemia) were associated with angiographic evidence of CHD and lower event-free survival after cardiovascular events [
         <a href="#rid82">
          82
         </a>
         ]. The severity of the PCOS phenotype may correlate with cardiovascular risk [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H360467531">
         <span class="h2">
          C-reactive protein
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum concentrations of C-reactive protein (CRP), a biochemical predictor of cardiovascular disease, appear to be commonly elevated in women with PCOS. As an example, in a retrospective analysis of 116 women with PCOS and 96 BMI-matched control women with regular menstrual cycles, serum CRP concentrations were high (&gt;5 mg/L) in 37 and 10 percent of PCOS and control subjects, respectively [
         <a href="#rid84">
          84
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1484.html" rel="external">
          "C-reactive protein in cardiovascular disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Endothelial function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endothelial dysfunction has been thought to be a contributing factor to the development of atherosclerosis. Data on endothelial function in women with PCOS are conflicting, with some [
         <a href="#rid85">
          85-88
         </a>
         ], but not all, studies [
         <a href="#rid89">
          89
         </a>
         ] reporting evidence of endothelial dysfunction in women with PCOS. Insulin resistance [
         <a href="#rid85">
          85,86
         </a>
         ]; high serum concentrations of testosterone [
         <a href="#rid86">
          86
         </a>
         ], CRP [
         <a href="#rid85">
          85
         </a>
         ], and total cholesterol [
         <a href="#rid86">
          86
         </a>
         ]; or low serum adiponectin concentrations [
         <a href="#rid88">
          88
         </a>
         ] were correlated with the observed endothelial dysfunction.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Functional and imaging studies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiography – Women with PCOS may have more extensive coronary disease on angiography when compared with normal women. This was illustrated in a report of 143 women younger than age 60 years who were undergoing coronary angiography for assessment of chest pain or valvular disease [
         <a href="#rid90">
          90
         </a>
         ]. Ultrasound appearance of polycystic ovarian morphology was present in 42 percent of the women and was associated with hirsutism, lower levels of high-density lipoprotein (HDL) cholesterol, and higher concentrations of free testosterone, triglycerides, and C-peptide, when compared with women with normal-appearing ovaries. The women with polycystic ovaries had more extensive coronary disease on angiography than those with normal ovaries. However, this study did not distinguish between polycystic morphology and true PCOS; thus, the applicability of these findings to women with PCOS is uncertain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carotid ultrasound – A tendency toward atherosclerosis was also suggested in an ultrasonographic study of 125 women with PCOS and 142 normal controls [
         <a href="#rid91">
          91
         </a>
         ]. Carotid artery intima-media thickness was significantly greater in women with PCOS who were ≥45 years old than in normal controls. However, the mean intima-media thickness in the PCOS group was still well below that seen in patients with significant carotid artery disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EBCT – Electron beam computed tomography (EBCT) is a noninvasive measure of coronary artery calcium (CAC, a marker for atherosclerosis). In a study of 36 premenopausal women (mean age 38 years) with PCOS, the presence of CAC was more common in PCOS patients when compared with a group of age- and weight-matched controls (39 versus 21 percent, respectively; odds ratio [OR] 2.4) [
         <a href="#rid92">
          92
         </a>
         ]. However, after controlling for BMI, PCOS was no longer a predictor of CAC, suggesting that obese women with or without PCOS are at increased risk of atherosclerosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A higher prevalence of CAC was observed in PCOS women compared with controls in two additional reports [
         <a href="#rid93">
          93,94
         </a>
         ]. In one, components of the metabolic syndrome (low HDL and insulin resistance) appeared to mediate the association between PCOS and CAC, independently of obesity [
         <a href="#rid93">
          93
         </a>
         ]. In the second, the increase in risk appeared to be independent of traditional cardiovascular risk factors and markers of inflammation [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H342300742">
         <span class="h1">
          VENOUS THROMBOEMBOLISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral contraceptives (OCs), the mainstay of therapy for women with PCOS, are associated with an increased risk of venous thromboembolism (VTE) in all users but particularly in women over age 40 years and those with obesity [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         Two studies based upon health insurance claims databases reported that PCOS itself appeared to be an additional risk factor for VTE [
         <a href="#rid96">
          96,97
         </a>
         ]. However, both had important methodological limitations, and it cannot be determined whether the excess risk of VTE in this population was due to PCOS or the presence of obesity and other comorbidities. Neither study directly addressed the question of whether OC use disproportionately increases VTE risk in women with PCOS.
        </p>
        <p>
         For most women with PCOS, the benefits of OCs still outweigh the potential risks of VTE. Thus, we still consider OCs to be first-line therapy for the management of hyperandrogenic symptoms, menstrual cycle control, and contraception. (See
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H342300978">
         <span class="h1">
          PSYCHOSOCIAL ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H3982093932">
         <span class="h2">
          Mood disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         We agree with expert societies that women with PCOS should be screened for depression and anxiety at the time of diagnosis [
         <a href="#rid98">
          98
         </a>
         ]. There is evidence that women with PCOS may be more likely to have mood disorders (depression and anxiety) when compared with women without PCOS [
         <a href="#rid57">
          57,99-105
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a cross-sectional study of 117 women with PCOS, 75 (61 percent) had depression that could not be explained by obesity or hyperandrogenic symptoms, as mean body mass index (BMI) and presence of hirsutism or acne was similar in the women with or without depression [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a longitudinal cohort study of women with PCOS who were screened for mood disorders at ages 31 and 46 years, the prevalence of anxiety and/or depression symptoms was higher than in control women and was independent of obesity and hyperandrogenism [
         <a href="#rid106">
          106
         </a>
         ]. At age 46 years, 25 percent of women with PCOS had depression compared with 12 percent in the control group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective cohort study of over 16,000 patients with PCOS and 16,000 controls (matched for age and obesity), the prevalence of depression and anxiety was significantly higher in the women with PCOS compared with controls (23 versus 19, 11.5 versus 9.3 percent, respectively) [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H247154836">
         <span class="h2">
          Eating disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with PCOS are also at risk for eating disorders, in particular, binge eating and bulimia nervosa [
         <a href="#rid108">
          108-111
         </a>
         ]. In one report, bulimia nervosa, binge, or any eating disorder, but not anorexia nervosa were more common in women with than without PCOS (odds ratio [OR] for any eating disorder 3.68, 95% CI 1.38-9.81) [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1524740400">
         <span class="h2">
          Overall quality of life
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to eating and mood disorders, women with PCOS are at risk for sleep disorders and sexual dysfunction. A number of studies have reported decreased health-related quality of life in women with PCOS [
         <a href="#rid107">
          107,112,113
         </a>
         ]. A meta-analysis of 36 studies reporting on 349,529 women reported that women with PCOS, when compared with those without PCOS, are more likely to have eating disorders as well as [
         <a href="#rid111">
          111
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep disorders (hypersomnia [OR 4.39, 95% CI 1.07-18.07] and obstructive sleep apnea [OR 10.81, 95% CI 2.39-48.83])
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sexual dysfunction (lower sexual satisfaction as measured on a visual analogue scale), but no difference in Total Female Sexual Function Index
        </p>
        <p>
        </p>
        <p>
         In addition to screening for mood and eating disorders, we suggest evaluating for sleep disorders and sexual dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/2093.html" rel="external">
          "Eating disorders: Overview of epidemiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5424.html" rel="external">
          "Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H342301107">
         <span class="h1">
          OTHER ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Factors affecting phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ethnic, racial, and other cultural factors influence the phenotype of PCOS as illustrated by the following findings [
         <a href="#rid114">
          114
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Black and Hispanic women were more likely and Asian women less likely than White women to be obese [
         <a href="#rid55">
          55
         </a>
         ]. After adjusting for body mass index (BMI), Asian and Hispanic women were more likely to have diabetes, and Black women were more likely to have hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mexican American women were more obese and had higher serum fasting insulin concentrations than White women [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Women in the United States, when compared with those in Italy, were more obese, more insulin resistant, and had lower serum high-density lipoprotein (HDL) concentrations [
         <a href="#rid116">
          116
         </a>
         ]. However, total calorie intake and dietary constituents were similar in the two groups, except that women in the United States ate more saturated fat. The authors hypothesized that diet alone did not explain the differences in body mass, and that genetic and lifestyle factors likely played a role.
        </p>
        <p>
        </p>
        <p>
         In a study comparing the phenotype of PCOS in White women in Boston or Iceland (BMI-matched), serum androstenedione concentrations were higher and serum luteinizing hormone (LH) and testosterone concentrations lower in the Icelandic compared with Boston women [
         <a href="#rid16">
          16
         </a>
         ]. Ovarian volumes and Ferriman-Gallwey scores were also lower in the Icelandic women, but there were no differences in fasting glucose or insulin levels between the two groups.
        </p>
        <p>
         In the same study, the phenotype of PCOS was compared among different ethnic groups in Boston. Serum insulin concentrations and homeostasis model assessment ([HOMA], a measure of insulin resistance) were higher in an African American subgroup in Boston compared with White and Asian women. However, these differences could be accounted for by BMI. There were no differences in sex steroid and gonadotropin levels among the different ethnic groups in Boston. These observations suggest that there are differences in the reproductive aspects of the PCOS phenotype in White Icelandic and White Boston women. In contrast, differences in insulin dynamics appear to be explained by differences in BMI and not country of origin or ethnic background.
        </p>
        <p>
         Some of the clinical features of PCOS have a familial pattern, including the risk of type 2 diabetes [
         <a href="#rid51">
          51-54
         </a>
         ], beta cell dysfunction [
         <a href="#rid53">
          53
         </a>
         ], dyslipidemia (including high low-density lipoprotein [LDL] concentrations) [
         <a href="#rid117">
          117,118
         </a>
         ], menstrual irregularity [
         <a href="#rid118">
          118
         </a>
         ], and insulin resistance and hyperandrogenemia [
         <a href="#rid119">
          119
         </a>
         ]. Although a number of candidate genes have been proposed, none have been verified in large populations [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7430.html" rel="external">
          "Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H360467558">
         <span class="h2">
          Reproductive aging/menopause
         </span>
         <span class="headingEndMark">
          —
         </span>
         Women with PCOS sometimes develop more regular menstrual cycles as they age [
         <a href="#rid120">
          120-122
         </a>
         ]; this is thought to be related to the age-dependent decline in serum androgens that both women with and without PCOS experience [
         <a href="#rid114">
          114,123
         </a>
         ]. Less is known about their menstrual patterns during the menopausal transition or their average age at menopause. Postmenopausal women with PCOS report more hirsutism symptoms, but fewer vasomotor symptoms than controls [
         <a href="#rid124">
          124
         </a>
         ]. Available data suggest that after menopause, clinical hyperandrogenism persists in spite of the eventual decline in serum androgens into the normal range.
        </p>
        <p>
         In one study of 20 postmenopausal women with PCOS (mean age 54 years) compared with 20 age-matched controls, serum androgens (androstenedione, dehydroepiandrosterone sulfate [DHEAS], total testosterone, and free androgen index) were higher in the PCOS group, while sex hormone-binding globulin (SHBG) levels were lower [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
         In a 30-year longitudinal cohort study of 33 women with PCOS (mean age 50 years at baseline) and 118 age-matched controls, serum androgens were higher than controls until approximately age 70 years, but then declined into the normal range (similar to controls) by a mean age of 81 years [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
         Hirsutism was more common in PCOS patients at all time points, including the final evaluation when serum androgens were normal. The generalizability of these data are unclear as all of the women with PCOS had undergone wedge resection in their 20s. (See
         <a class="medical medical_review" href="/z/d/html/7421.html" rel="external">
          "Treatment of polycystic ovary syndrome in adults", section on 'Laparoscopic surgery'
         </a>
         .)
        </p>
        <p>
         Other observations in postmenopausal women with PCOS include higher C-reactive protein (CRP) concentrations and a greater insulin response to an oral glucose tolerance test (OGTT) compared with controls [
         <a href="#rid127">
          127,128
         </a>
         ].
        </p>
        <p>
         There are concerns that women with PCOS are at higher risk for coronary heart disease (CHD) after menopause, but data are limited. In a report from the longitudinal cohort study described above, hypertension and hypertriglyceridemia were more common in the PCOS group, while myocardial infarction, stroke, diabetes, cancer, and mortality prevalence was similar in the two cohorts with similar BMI [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H700357742">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110097.html" rel="external">
          "Society guideline links: Polycystic ovary syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110632.html" rel="external">
          "Society guideline links: Hirsutism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15605.html" rel="external">
          "Patient education: Polycystic ovary syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/2163.html" rel="external">
          "Patient education: Polycystic ovary syndrome (PCOS) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common endocrinopathy
         </strong>
         – Polycystic ovary syndrome (PCOS) is thought to be one of the most common endocrinopathies in women, affecting between 6.5 and 8 percent of women overall. The syndrome is characterized clinically by oligomenorrhea and hyperandrogenism, as well as the frequent presence of associated risk factors for cardiovascular disease, including obesity, glucose intolerance, dyslipidemia, and obstructive sleep apnea (OSA).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reproductive abnormalities
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Menstrual dysfunction characterized by infrequent or absent menses. However, some women with PCOS have abnormal uterine bleeding as a result of their chronic anovulation. The ovulatory dysfunction typically results in infertility and the need for ovulation induction in those who wish to conceive. (See
         <a class="local">
          'Menstrual dysfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Typical polycystic appearance of the ovaries on transvaginal ultrasound in the majority of women with irregular menses and hyperandrogenism (using the original ultrasound criteria for polycystic ovaries) [
         <a href="#rid129">
          129
         </a>
         ]. However, this ultrasound appearance is nonspecific, as it may also be seen in normal-cycling women (see
         <a class="local">
          'Ultrasound appearance'
         </a>
         above). The ultrasound diagnostic criteria for PCOS are reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">
          "Diagnosis of polycystic ovary syndrome in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyperandrogenism
         </strong>
         – Hyperandrogenism, which may include clinical signs (hirsutism, acne, alopecia) and/or elevated serum androgen concentrations. (See
         <a class="local">
          'Hyperandrogenism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Metabolic issues
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A clustering of risk factors for diabetes and cardiovascular disease, including obesity (and insulin resistance), glucose intolerance, and dyslipidemia. (See
         <a class="local">
          'Obesity and insulin resistance'
         </a>
         above and
         <a class="local">
          'Dyslipidemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Women with PCOS are at increased risk for type 2 diabetes, but an excess risk of cardiovascular disease has not yet been demonstrated definitively. (See
         <a class="local">
          'IGT/type 2 diabetes'
         </a>
         above and
         <a class="local">
          'Coronary heart disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other clinical manifestations that may be seen include sleep apnea and nonalcoholic steatohepatitis (NASH). (See
         <a class="local">
          'Sleep apnea'
         </a>
         above and
         <a class="local">
          'Nonalcoholic fatty liver disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Women with PCOS may be more likely to have mood disorders (depression and anxiety). In addition, PCOS appears to be associated with an increased risk of eating disorders, in particular, binge eating. (See
         <a class="local">
          'Psychosocial issues'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016; 31:2841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldstreicher J, Santoro NF, Hall JE, et al. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab 1994; 79:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou R, Bird IM, Dumesic DA, Abbott DH. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:6630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J Clin Endocrinol Metab 2006; 91:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes MG, Urbanek M, Ehrmann DA, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun 2015; 6:7502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gottschau M, Kjaer SK, Jensen A, et al. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol 2015; 136:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giudice LC. Endometrium in PCOS: Implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 2006; 20:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 2001; 98:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poruondo JA, Tejada RF, Benito JA, Bilbao FJ. Laparoscopy, ovarian and endometrial biopsies in secondary amenorrhea. Endoscopy 1982; 14:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welt CK, Arason G, Gudmundsson JA, et al. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. J Clin Endocrinol Metab 2006; 91:4361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 2004; 89:4343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy MK, Hall JE, Adams JM, et al. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:3878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason HD, Willis DS, Beard RW, et al. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J Clin Endocrinol Metab 1994; 79:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webber LJ, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary. Lancet 2003; 362:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril 2011; 95:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 2014; 211:59.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013; 98:3332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laven JS, Mulders AG, Visser JA, et al. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moolhuijsen LME, Louwers YV, Laven JSE, Visser JA. Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2022; 107:e3714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993; 8:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joham AE, Ranasinha S, Zoungas S, et al. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99:E447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qin JZ, Pang LH, Li MJ, et al. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013; 11:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Falbo A, Chiossi G, et al. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. J Clin Endocrinol Metab 2014; 99:2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinehr T, de Sousa G, Roth CL, Andler W. Androgens before and after weight loss in obese children. J Clin Endocrinol Metab 2005; 90:5588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCartney CR, Prendergast KA, Chhabra S, et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab 2006; 91:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeVane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinola P, Piltonen TT, Puurunen J, et al. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study. J Clin Endocrinol Metab 2015; 100:3400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril 1984; 41:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwimmer JB, Khorram O, Chiu V, Schwimmer WB. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setji TL, Holland ND, Sanders LL, et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cerda C, Pérez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med 2000; 109:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 2004; 27:2444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005; 106:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Sturis J, Byrne MM, et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995; 96:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001; 86:2027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrmann DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo JC, Feigenbaum SL, Yang J, et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90:3236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson RL, Buckley JD, Lim SS, et al. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2010; 94:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodarzi MO, Erickson S, Port SC, et al. beta-Cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ 2007; 176:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmert MR, Gordon CM, Kartashov AI, et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci U S A 1995; 92:10619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waterworth DM, Bennett ST, Gharani N, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997; 349:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helvaci N, Karabulut E, Demir AU, Yildiz BO. Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature. Endocr Connect 2017; 6:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001; 86:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fogel RB, Malhotra A, Pillar G, et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tasali E, Van Cauter E, Hoffman L, Ehrmann DA. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:3878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 37:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998; 51:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legro RS, Azziz R, Ehrmann D, et al. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003; 88:5137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berneis K, Rizzo M, Lazzarini V, et al. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelan N, O'Connor A, Kyaw-Tun T, et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab 2010; 95:3933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002; 186:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang ET, Cirillo PM, Vittinghoff E, et al. Menstrual irregularity and cardiovascular mortality. J Clin Endocrinol Metab 2011; 96:E114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jovanovic VP, Carmina E, Lobo RA. Not all women diagnosed with PCOS share the same cardiovascular risk profiles. Fertil Steril 2010; 94:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89:2160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarkun I, Arslan BC, Cantürk Z, et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89:5592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:5088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86:4666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmina E, Orio F, Palomba S, et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006; 119:356.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85:1851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997; 126:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20:2414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christian RC, Dumesic DA, Behrenbeck T, et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:2562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talbott EO, Zborowski JV, Rager JR, et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89:5454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shroff R, Kerchner A, Maifeld M, et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. J Clin Endocrinol Metab 2007; 92:4609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourdy P, Bachelot A, Catteau-Jonard S, et al. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol (Paris) 2012; 73:469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okoroh EM, Hooper WC, Atrash HK, et al. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. Am J Obstet Gynecol 2012; 207:377.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bird ST, Hartzema AG, Brophy JM, et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2013; 185:E115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dokras A, Stener-Victorin E, Yildiz BO, et al. Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertil Steril 2018; 109:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril 2010; 93:2421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril 2010; 94:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rassi A, Veras AB, dos Reis M, et al. Prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry 2010; 51:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2011; 26:2442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2012; 97:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dokras A, Clifton S, Futterweit W, Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet Gynecol 2011; 117:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update 2012; 18:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karjula S, Morin-Papunen L, Auvinen J, et al. Psychological Distress Is More Prevalent in Fertile Age and Premenopausal Women with PCOS Symptoms -15-yr Follow-up. J Clin Endocrinol Metab 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berni TR, Morgan CL, Berni ER, Rees DA. Polycystic Ovary Syndrome Is Associated With Adverse Mental Health and Neurodevelopmental Outcomes. J Clin Endocrinol Metab 2018; 103:2116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naessén S, Carlström K, Garoff L, et al. Polycystic ovary syndrome in bulimic women--an evaluation based on the new diagnostic criteria. Gynecol Endocrinol 2006; 22:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan J, Scholtz S, Lacey H, Conway G. The prevalence of eating disorders in women with facial hirsutism: an epidemiological cohort study. Int J Eat Disord 2008; 41:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee I, Cooney LG, Saini S, et al. Increased risk of disordered eating in polycystic ovary syndrome. Fertil Steril 2017; 107:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thannickal A, Brutocao C, Alsawas M, et al. Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2020; 92:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veras AB, Bruno RV, de Avila MA, Nardi AE. Sexual dysfunction in patients with polycystic ovary syndrome: clinical and hormonal correlations. Compr Psychiatry 2011; 52:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cesta CE, Månsson M, Palm C, et al. Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort. Psychoneuroendocrinology 2016; 73:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kauffman RP, Baker VM, Dimarino P, et al. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol 2002; 187:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmina E, Legro RS, Stamets K, et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003; 18:2289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90:4797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sam S, Legro RS, Essah PA, et al. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006; 103:7030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88:2031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000; 15:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elting MW, Kwee J, Korsen TJ, et al. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 2003; 79:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vulpoi C, Lecomte C, Guilloteau D, Lecomte P. Ageing and reproduction: is polycystic ovary syndrome an exception? Ann Endocrinol (Paris) 2007; 68:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winters SJ, Talbott E, Guzick DS, et al. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000; 73:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab 2011; 96:2178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markopoulos MC, Rizos D, Valsamakis G, et al. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab 2011; 96:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forslund M, Schmidt J, Brännström M, et al. Reproductive Hormones and Anthropometry: A Follow-Up of PCOS and Controls From Perimenopause to Older Than 80 Years. J Clin Endocrinol Metab 2021; 106:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puurunen J, Piltonen T, Morin-Papunen L, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab 2011; 96:1827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 2011; 96:3794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986; 293:355.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7436 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15788499" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15181052" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The prevalence and features of the polycystic ovary syndrome in an unselected population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27664216" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2961784" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9215302" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962325" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16174719" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16522691" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26284813" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25451694" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24688118" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16772154" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Endometrium in PCOS: Implantation and predisposition to endocrine CA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11506853" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6216099" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Laparoscopy, ovarian and endometrial biopsies in secondary amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30033227" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16940441" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356031" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16882750" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7962330" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14522531" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Formation and early development of follicles in the polycystic ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21074758" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24593938" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775353" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14715867" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16368745" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35737957" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Amenorrhea associated with bilateral polycystic ovaries
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8345091" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12407039" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24081730" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23800002" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24873996" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16014405" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Androgens before and after weight loss in obese children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16492701" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/125040" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29522147" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18950759" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14764747" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Androgen excess in women: experience with over 1000 consecutive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26192874" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6425087" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Hyperprolactinemia in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2670645" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15866584" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705403" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Abnormal aminotransferase activity in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16492691" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17560682" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11063962" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15451914" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Increasing prevalence of the metabolic syndrome among u.s. Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15623819" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994628" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Screening women with polycystic ovary syndrome for metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16249284" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10333916" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7615824" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11344202" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507516" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16434451" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15797965" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20004371" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507511" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : beta-Cell function: a key pathological determinant in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9920077" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17389441" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11889155" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635975" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7479852" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9100625" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739562" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11158002" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11238505" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16219719" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18647805" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1395062" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9619969" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11755503" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21247558" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14602740" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17062762" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20519354" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11810081" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Polycystic ovary syndrome: a risk for coronary artery disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9674665" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Mortality of women with polycystic ovary syndrome at long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10792339" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11994334" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Menstrual cycle irregularity and risk for future cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20980429" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Menstrual irregularity and cardiovascular mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182456" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19501355" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Not all women diagnosed with PCOS share the same cardiovascular risk profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15126536" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15531516" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15985492" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Predictors of endothelial dysfunction in young women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11600523" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16564785" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Endothelial dysfunction in PCOS: role of obesity and adipose hormones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10843164" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8992921" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11073846" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12788855" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15531497" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17848406" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23078975" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959762" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23209115" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29778388" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Androgen Excess- Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20117778" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19896652" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20965306" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Prevalence of psychiatric disorders in patients with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21725075" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22127370" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21173657" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22824735" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Psychological Distress Is More Prevalent in Fertile Age and Premenopausal Women with PCOS Symptoms -15-yr Follow-up
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29648599" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Polycystic Ovary Syndrome Is Associated With Adverse Mental Health and Neurodevelopmental Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16864149" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Polycystic ovary syndrome in bulimic women--an evaluation based on the new diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18433027" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : The prevalence of eating disorders in women with facial hirsutism: an epidemiological cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28104244" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Increased risk of disordered eating in polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31917860" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21193185" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Sexual dysfunction in patients with polycystic ovary syndrome: clinical and hormonal correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27513883" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Polycystic ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a nationwide Swedish cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22153789" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12439532" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14585875" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15899949" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16632599" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12727950" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10611183" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Women with polycystic ovary syndrome gain regular menstrual cycles when ageing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12738511" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17316546" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Ageing and reproduction: is polycystic ovary syndrome an exception?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10731532" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21508129" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21177795" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33205205" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Reproductive Hormones and Anthropometry: A Follow-Up of PCOS and Controls From Perimenopause to Older Than 80 Years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21450988" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21956415" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3089520" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
